Form 4 holding
Director
TEREX CORP
- Security class
- Common Stock, $ .01 par value
- Shares / value
- 64,456
- Estimated value
- $3,440,661
- Report date
- 02 Feb 2026
- Price
- $53.38
- Ownership
- Direct
John Canan
Insider Reports History
- Reporting-owner location
- Milwaukee, WI
- Latest reporting-owner signature
-
/s/ Scott J. Posner by power of attorney
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for John Canan
Form 4 holding
Director
REV Group, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 02 Feb 2026
- Price
- $60.81
- Ownership
- Direct
Form 4 holding
Director
Acasti Pharma Inc.
- Security class
- Stock Options (Right to Buy)
- Shares / value
- 45,000
- Estimated value
- Report date
- 28 Sep 2022
- Price
- Ownership
- Direct
- Underlying class
- Class A Common Shares
- Underlying amount
Insider Reports Filed by John Canan
4
TEX
TEREX CORP
- Report period
- 02 Feb 2026
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 04 Feb 2026, 12:51
- Role
- Director
- Next action
- Open filing details
3
TEX
TEREX CORP
- Report period
- 02 Feb 2026
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 04 Feb 2026, 12:48
- Role
- Director
- Next action
- Open filing details
4
REVG
REV Group, Inc.
- Report period
- 02 Feb 2026
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 02 Feb 2026, 19:04
- Role
- Director
- Next action
- Open filing details
4
REVG
REV Group, Inc.
- Report period
- 03 Dec 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 05 Dec 2025, 20:40
- Role
- Director
- Next action
- Open filing details
4
REVG
REV Group, Inc.
- Report period
- 05 Dec 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 09 Dec 2024, 20:11
- Role
- Director
- Next action
- Open filing details
4
REVG
REV Group, Inc.
- Report period
- 08 Dec 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 12 Dec 2023, 19:13
- Role
- Director
- Next action
- Open filing details
4
REVG
REV Group, Inc.
- Report period
- 08 Dec 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 12 Dec 2022, 15:05
- Role
- Director
- Next action
- Open filing details
4
GRCE
Acasti Pharma Inc.
- Report period
- 28 Sep 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 30 Sep 2022, 16:19
- Role
- Director
- Next action
- Open filing details
4
REVG
REV Group, Inc.
- Report period
- 09 Dec 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 13 Dec 2021, 16:10
- Role
- Director
- Next action
- Open filing details
4
GRCE
Acasti Pharma Inc.
- Report period
- 12 Nov 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 16 Nov 2021, 15:16
- Role
- Director
- Next action
- Open filing details